DK1695983T3 - Glucagon-lignende peptid-1 analoger - Google Patents

Glucagon-lignende peptid-1 analoger

Info

Publication number
DK1695983T3
DK1695983T3 DK06114553T DK06114553T DK1695983T3 DK 1695983 T3 DK1695983 T3 DK 1695983T3 DK 06114553 T DK06114553 T DK 06114553T DK 06114553 T DK06114553 T DK 06114553T DK 1695983 T3 DK1695983 T3 DK 1695983T3
Authority
DK
Denmark
Prior art keywords
glucagon
peptide
analogues
glp
compounds
Prior art date
Application number
DK06114553T
Other languages
Danish (da)
English (en)
Inventor
Wolfgang Glaesner
Rohn Millican
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1695983T3 publication Critical patent/DK1695983T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06114553T 2000-06-16 2001-06-01 Glucagon-lignende peptid-1 analoger DK1695983T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21217100P 2000-06-16 2000-06-16
US24034900P 2000-10-13 2000-10-13
PCT/US2001/016474 WO2001098331A2 (en) 2000-06-16 2001-06-01 Glucagon-like peptide-1 analogs

Publications (1)

Publication Number Publication Date
DK1695983T3 true DK1695983T3 (da) 2009-05-18

Family

ID=26906843

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01939252T DK1294757T3 (da) 2000-06-16 2001-06-01 Glucagonlignende peptid 1-analoger
DK06114553T DK1695983T3 (da) 2000-06-16 2001-06-01 Glucagon-lignende peptid-1 analoger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK01939252T DK1294757T3 (da) 2000-06-16 2001-06-01 Glucagonlignende peptid 1-analoger

Country Status (33)

Country Link
US (2) US7084243B2 (de)
EP (2) EP1294757B1 (de)
JP (1) JP4716641B2 (de)
KR (1) KR100847615B1 (de)
CN (1) CN100469791C (de)
AR (1) AR031701A1 (de)
AT (2) ATE424413T1 (de)
AU (2) AU2001264791B2 (de)
BR (1) BR0111562A (de)
CA (1) CA2412004C (de)
CY (2) CY1105917T1 (de)
CZ (1) CZ304002B6 (de)
DE (2) DE60137876D1 (de)
DK (2) DK1294757T3 (de)
DZ (1) DZ3388A1 (de)
EA (1) EA008837B1 (de)
EG (1) EG24755A (de)
ES (2) ES2275685T3 (de)
HK (1) HK1055121A1 (de)
HR (1) HRP20020996B1 (de)
HU (2) HU229208B1 (de)
IL (2) IL153453A0 (de)
MX (1) MXPA02012203A (de)
MY (1) MY137350A (de)
NO (1) NO330686B1 (de)
NZ (1) NZ522330A (de)
PE (1) PE20011363A1 (de)
PL (1) PL206302B1 (de)
PT (2) PT1294757E (de)
SI (1) SI1695983T1 (de)
SK (1) SK287757B6 (de)
TW (1) TWI321134B (de)
WO (1) WO2001098331A2 (de)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000654A2 (en) 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ATE424413T1 (de) * 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2002022151A2 (en) 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
EP1412384B1 (de) * 2001-06-28 2007-12-26 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
CN1363654A (zh) 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
EP1432730A4 (de) * 2001-08-23 2006-10-11 Lilly Co Eli Analoga des glucagon-like peptide-1
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
IL160917A0 (en) * 2001-10-18 2004-08-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP2261250B1 (de) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin Fusionsproteine
WO2003059372A2 (en) * 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and a modulator of diabetic late complications
ES2614603T3 (es) * 2002-02-20 2017-06-01 Emisphere Technologies, Inc. Procedimiento de administración de moléculas GLP-1
DE60318938T2 (de) 2002-03-20 2009-01-22 Mannkind Corp., Valencia Inhalationsgerät
WO2003103572A2 (en) * 2002-06-04 2003-12-18 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2004067548A2 (en) * 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1594529B1 (de) * 2003-02-19 2010-01-20 Ipsen Pharma Glp-1-analoga
WO2004103390A2 (en) 2003-05-15 2004-12-02 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
EP2292254A3 (de) * 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilisierte pharmazeutische Peptidzusammensetzungen
JP2007524592A (ja) * 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
KR100758755B1 (ko) 2003-06-12 2007-09-14 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 유사체 융합 단백질
CA2545034C (en) 2003-11-20 2013-03-05 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
EP2210900A3 (de) 2003-12-16 2010-08-11 Ipsen Pharma GlLP-1-Analoga
US7521527B2 (en) * 2003-12-16 2009-04-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. GLP-1 pharmaceutical compositions
JP2007537149A (ja) 2004-01-08 2007-12-20 セラテクノロジーズ インコーポレイテッド 長時間作用性のグルカゴン様ペプチド−１類似体
CA2897475C (en) 2004-04-30 2018-07-10 Dow Agrosciences Llc Novel herbicide resistance genes
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
EP2316446A1 (de) 2004-06-11 2011-05-04 Novo Nordisk A/S Bekämpfung von Arzneimittel-induzierter Fettleibigkeit unter Verwendung von GLP-1-Agonisten
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
JP4990142B2 (ja) 2004-08-23 2012-08-01 マンカインド コーポレイション 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩
PL1789434T3 (pl) * 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
JP2008515856A (ja) * 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
EP1799711B1 (de) 2004-10-07 2012-06-20 Novo Nordisk A/S Zeitverzögerte exendin-4-verbindungen
EP1817048B1 (de) 2004-11-12 2014-02-12 Novo Nordisk A/S Stabile formulierungen insulinoptropischer peptide
EP2505207B1 (de) 2005-01-14 2015-04-22 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modifizierte Exendine und Anwendungen davon
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1864661A1 (de) * 2005-03-18 2007-12-12 Ajinomoto Co., Inc. Prophylaktisches/therapeutisches mittel gegen stressbedingte darmerkrankung
US8183340B2 (en) * 2005-05-13 2012-05-22 Eli Lilly And Company GLP-1 pegylated compounds
EA012287B1 (ru) * 2005-06-30 2009-08-28 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С. Фармацевтическая композиция glp-1
HUE028691T2 (en) 2005-09-14 2016-12-28 Mannkind Corp A method for formulating a drug based on increasing the affinity of crystalline microparticle surfaces towards active ingredients
AU2006308959B2 (en) 2005-10-28 2012-09-06 Corteva Agriscience Llc Novel herbicide resistance genes
ES2572952T3 (es) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
CA2634034A1 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2008063203A2 (en) * 2006-01-27 2008-05-29 Whitehead Institute For Biomedical Research Compositions and methods for efficient gene silencing in plants
AU2007216966C1 (en) 2006-02-22 2014-03-20 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
WO2007124461A2 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
EP2020990B1 (de) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
AU2007269622A1 (en) * 2006-07-06 2008-01-10 Amylin Pharmaceuticals, Inc. Glucagon-like peptides and uses thereof
AR061930A1 (es) 2006-07-18 2008-10-01 Centocor Inc Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
KR100851560B1 (ko) * 2006-12-27 2008-08-11 고려대학교 산학협력단 새로운 글루카곤 유사 펩타이드-1 (ｇｌｐ-1) 작용제 및 그용도
ES2628063T3 (es) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
CN101041693B (zh) * 2007-02-06 2011-08-17 珠海联邦制药股份有限公司 一种降血糖多肽及其应用
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
GB2448895A (en) * 2007-05-01 2008-11-05 Activotec Spp Ltd GLP-1 like compounds and uses thereof
US8464239B2 (en) * 2007-06-11 2013-06-11 Red Hat, Inc. Real-time installation and/or configuration assistant
EP3260129A1 (de) 2007-08-03 2017-12-27 Eli Lilly and Company Verwendung einer fgf-21-verbindung und glp-1-verbindung zur behandlung von diabetes
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
KR20130123470A (ko) * 2007-10-24 2013-11-12 맨카인드 코포레이션 활성제의 전달
KR101736502B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Ｇｌｐ-1에 의한 유해 효과의 예방 방법
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2655921T3 (es) 2008-06-13 2018-02-22 Mannkind Corporation Un inhalador de polvo seco y sistema para administración de fármacos
KR20110040760A (ko) 2008-06-17 2011-04-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 질환 및 비만 치료용 ｇｉｐ-기초된 혼합형 항진제
CN103641907A (zh) 2008-06-17 2014-03-19 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
CN104447980A (zh) * 2008-06-17 2015-03-25 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
ES2904623T3 (es) 2008-06-20 2022-04-05 Mannkind Corp Aparato interactivo para establecer un perfil en tiempo real de esfuerzos de inhalación
EP2926825A1 (de) 2008-06-27 2015-10-07 Duke University Therapeutika mit elastinähnlichen peptiden
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
CN101337989B (zh) * 2008-08-28 2012-10-24 中国药科大学 一类新型胰高血糖素样肽-1(glp-1)类似物及其应用
CN101367873B (zh) * 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
ES2614427T3 (es) 2008-11-07 2017-05-31 The General Hospital Corporation Fragmentos C-terminales de péptido glucagonoide 1 (GLP-1)
EP2376097A4 (de) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp Amidbasierte peptid-prodrugs der glucagon-superfamilie
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2405963B1 (de) 2009-03-11 2013-11-06 MannKind Corporation Gerät, system und verfahren zur messung von widerstand in einem inhaliergerät
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
SG10201407329RA (en) 2009-08-14 2015-01-29 Phasebio Pharmaceuticals Inc Modified vasoactive intestinal peptides
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
BR112012011467A2 (pt) * 2009-10-30 2019-09-24 Otsuka Chemical Co Ltd forma glicosilada de análogo ao glp-1 antigênico.
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
AU2010323117B2 (en) 2009-11-25 2015-09-03 Capsugel Belgium Nv Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
BR112012018585A2 (pt) 2010-01-27 2017-01-10 Univ Indiana Res & Tech Corp conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
BR112012028707A2 (pt) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
CA2797095A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
AU2010353685B2 (en) * 2010-05-17 2014-09-25 Betta Pharmaceuticals Co., Ltd. Novel glucagon like peptide analogs, composition, and method of use
KR20130117755A (ko) 2010-06-21 2013-10-28 맨카인드 코포레이션 건조 분말 약물 운반 시스템 및 방법
JP2013540102A (ja) 2010-06-24 2013-10-31 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ
CN103080125A (zh) 2010-07-02 2013-05-01 安吉奥开米公司 用于治疗性结合物的短且含d氨基酸的多肽及其使用
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
JP6086067B2 (ja) 2010-12-22 2017-03-01 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Ｇｉｐレセプター活性を示すグルカゴンアナローグ
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN105667994B (zh) 2011-04-01 2018-04-06 曼金德公司 用于药物药盒的泡罩包装
CN102180963B (zh) * 2011-04-22 2014-06-25 中国药科大学 胰高血糖素样肽-1(glp-1)类似物及其应用
CN102219850A (zh) * 2011-05-03 2011-10-19 上海格尼生物技术有限公司 新的长效glp-1化合物
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012273365A1 (en) 2011-06-22 2014-01-16 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
PT2723367T (pt) 2011-06-22 2017-08-11 Univ Indiana Res & Tech Corp Co-agonistas do recetor da glucagina/glp-1
EP2729157B1 (de) 2011-07-06 2019-01-16 The General Hospital Corporation Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung
MX354705B (es) * 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
WO2013063160A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
CN103087177A (zh) * 2012-11-30 2013-05-08 中国药科大学 一类长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087175A (zh) * 2012-11-30 2013-05-08 中国药科大学 新型长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087178A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087179A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087176A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
JP6523247B2 (ja) 2013-03-15 2019-05-29 マンカインド コーポレイション 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP3021834A1 (de) 2013-07-18 2016-05-25 MannKind Corporation Hitzestabile pharmazeutische trockenpulverzusammensetzungen und verfahren
EP3030294B1 (de) 2013-08-05 2020-10-07 MannKind Corporation Insufflationsvorrichtung
CN104262481B (zh) * 2013-08-09 2018-02-09 天津药物研究院有限公司 一种侧链修饰的长效glp‑1类似物的制备方法及其应用
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10413593B2 (en) * 2014-10-24 2019-09-17 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and GLP-1 receptors
CN114652817A (zh) 2015-02-09 2022-06-24 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
EP3302354B1 (de) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
EP3398961B1 (de) * 2015-12-31 2022-06-29 Hanmi Pharm. Co., Ltd. Dreifachaktivator zur aktivierung von glucagon, glp-1 und gip-rezeptor
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
PL3474820T3 (pl) 2017-08-24 2024-05-13 Novo Nordisk A/S Kompozycje glp-1 i ich zastosowania
WO2019140021A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
HUE060135T2 (hu) 2018-04-05 2023-02-28 Sun Pharmaceutical Ind Ltd Új GLP-1 analógok
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
AU2019357621A1 (en) 2018-10-11 2021-05-27 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
WO2020087305A1 (zh) * 2018-10-30 2020-05-07 刘建宁 具有glp-1受体激动剂活性的glp-1多肽及其用途
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
EP4106724A1 (de) 2020-02-18 2022-12-28 Novo Nordisk A/S Glp-1-zusammensetzungen und verwendungen davon
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
JP3262329B2 (ja) * 1990-01-24 2002-03-04 アイ． バックレイ，ダグラス 糖尿病治療に有用なｇｌｐ―１アナログ
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1999007404A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
ATE381939T1 (de) 1997-11-14 2008-01-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
AU756836B2 (en) 1997-11-14 2003-01-23 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
AU2610699A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
EP1306091A3 (de) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation der Beta-Zellen Vermehrung
US6429197B1 (en) * 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
ATE424413T1 (de) * 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
CZ308214B6 (cs) * 2000-12-07 2020-03-04 Eli Lilly And Company GLP-1 fúzní proteiny
DE60228972D1 (de) * 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
AU2010279305A1 (en) * 2009-08-07 2012-03-01 Perry Felix Method and apparatus for surface and subsurface sanitizing of food products in a cooking appliance using ultraviolet light

Also Published As

Publication number Publication date
US7498308B2 (en) 2009-03-03
NO20025949L (no) 2002-12-11
NO20025949D0 (no) 2002-12-11
CY1105917T1 (el) 2011-04-06
CY1109061T1 (el) 2014-07-02
PT1695983E (pt) 2009-05-05
MXPA02012203A (es) 2003-06-06
KR100847615B1 (ko) 2008-07-21
CZ20024088A3 (cs) 2003-05-14
MY137350A (en) 2009-01-30
HU229208B1 (en) 2013-09-30
BR0111562A (pt) 2003-04-15
AU6479101A (en) 2002-01-02
PL360406A1 (en) 2004-09-06
US7084243B2 (en) 2006-08-01
EA008837B1 (ru) 2007-08-31
HK1055121A1 (en) 2003-12-24
EP1294757B1 (de) 2006-11-22
JP4716641B2 (ja) 2011-07-06
DZ3388A1 (fr) 2001-12-27
JP2004501162A (ja) 2004-01-15
PL206302B1 (pl) 2010-07-30
SK17782002A3 (sk) 2003-07-01
CN100469791C (zh) 2009-03-18
CN1468258A (zh) 2004-01-14
WO2001098331A2 (en) 2001-12-27
NZ522330A (en) 2004-11-26
NO330686B1 (no) 2011-06-06
PT1294757E (pt) 2007-02-28
ATE424413T1 (de) 2009-03-15
SI1695983T1 (sl) 2009-08-31
HU229108B1 (en) 2013-09-30
SK287757B6 (sk) 2011-08-04
EP1695983B1 (de) 2009-03-04
CA2412004C (en) 2010-12-21
EP1294757A2 (de) 2003-03-26
DE60137876D1 (de) 2009-04-16
CZ304002B6 (cs) 2013-08-14
EG24755A (en) 2010-07-26
IL153453A (en) 2009-11-18
AR031701A1 (es) 2003-10-01
PE20011363A1 (es) 2002-01-15
CA2412004A1 (en) 2001-12-27
EP1695983A2 (de) 2006-08-30
DE60124710T2 (de) 2007-09-13
US20030220243A1 (en) 2003-11-27
DE60124710D1 (de) 2007-01-04
HUP0301212A3 (en) 2004-09-28
US20060263849A1 (en) 2006-11-23
EP1695983A3 (de) 2007-02-21
TWI321134B (en) 2010-03-01
ATE346093T1 (de) 2006-12-15
DK1294757T3 (da) 2007-03-19
WO2001098331A3 (en) 2003-01-03
HRP20020996A2 (en) 2004-02-29
ES2321439T3 (es) 2009-06-05
ES2275685T3 (es) 2007-06-16
AU2001264791B2 (en) 2006-11-23
IL153453A0 (en) 2003-07-06
HRP20020996B1 (en) 2011-09-30
EA200300026A1 (ru) 2003-04-24
KR20030009537A (ko) 2003-01-29
HUP0301212A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
DK1695983T3 (da) Glucagon-lignende peptid-1 analoger
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
ATE396738T1 (de) Verwendung von glp-2-peptiden
NO2010010I1 (no) Exendin-4 (Exenatid)
DE60035138D1 (de) 1,3-dihydro-1-oxo-2H-Indenderivat
DE69922043D1 (de) Glp-1 analoge
ZA9811466B (en) Glucagon-like peptide-1 crystals.
EA200401345A1 (ru) Лечение гастропареза
DE69426021D1 (de) Xamonelin-Tartrat
WO1999053064A3 (en) Methods of delivering glp-1
UA88862C2 (en) Glucagon-like peptide-1 analogs
Manukhin On using the power cross section of elastic interaction; K voprosu ob ispol'zovanii stepennogo secheniya uprugogo vzaimodejstviya
SV2002000484A (es) Analogos del peptido-1 semejante a glucacon ref. x-13989
ITTO910461A1 (it) Procedimento di montaggio dell'elettrodo in carbone grafitico per un elettrolizzatore.
ITPN910075A1 (it) Procedimento di costruzione di telai in fibra di carbonio.
ITRM20010376A0 (it) Elettrodo-catetere per pacemaker per l'elettrostimolazione cardiaca bi-ventricolare.
ITGE980089A1 (it) Apparato per trattamenti fisiologici.